Security
Vaxart, Inc Common Stock · VXRT
VXRTOTCCommon stockCurrentCIK 72444Updated Oct 21, 2026
Name history
Aviragen Therapeutics, Inc. · through Feb 15, 2018Biota Pharmaceuticals, Inc. · through Apr 13, 2016NABI BIOPHARMACEUTICALS · through Nov 8, 2012NABI BIOPHARMACEUTICALS · through Jun 29, 2010NABI /DE/ · through Feb 14, 2002NORTH AMERICAN BIOLOGICALS INC · through Feb 14, 1996
VXRT price & chart
Loading TradingView…
OTC:VXRT on TradingView ↗About the company
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
In the news
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital ↗
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program News provided by Dynavax Technologies Nov 05, 2025, 16:01 ET Share this article Share to X Share this article Share to X HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY in ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Other Events
Items 8.01
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Items 5.07, 7.01, 9.01
Other Events
Items 8.01, 9.01
DEFA14A filing
DEFA14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 208,988,000Source | 166,674,000Source | 165,185,000Source | 164,085,000Source | 113,749,000Source | 180,055,000Source | 158,559,000Source | 88,670,000Source | 186,079,000Source | 166,389,000Source | 91,830,000Source | 153,847,000Source |
| Property, Plant and Equipment, NetUSD | 6,064,000Source | 9,476,000Source | 5,505,000Source | 6,926,000Source | 10,280,000Source | 4,827,000Source | 7,821,000Source | 11,102,000Source | 5,433,000Source | 8,705,000Source | 11,731,000Source | 15,585,000Source |
| GoodwillUSD | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,009,000Source | 3,740,000Source | 2,461,000Source | 3,192,000Source | 3,923,000Source | 2,643,000Source | 3,375,000Source | 4,106,000Source | 2,826,000Source | 3,557,000Source | 4,289,000Source | 5,020,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 22,035,000Source | — | — | — | — | — | 26,735,000Source | — | — | 34,755,000Source | 44,013,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 42,716,000Source | 591,000Source | 11,000Source | 4,281,000Source | 1,088,000Source | 7,139,000Source | 1,500,000Source | 556,000Source | 14,564,000Source | 5,761,000Source | 3,008,000Source | 20,000Source |
| Assets, CurrentUSD | 117,370,000Source | 66,456,000Source | 116,691,000Source | 70,379,000Source | 71,535,000Source | 131,704,000Source | 62,645,000Source | 44,284,000Source | 136,123,000Source | 68,260,000Source | 45,536,000Source | 99,451,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,632,000Source | 4,069,000Source | 5,723,000Source | 3,046,000Source | 4,165,000Source | 13,108,000Source | 4,585,000Source | 7,064,000Source | 20,971,000Source | 4,568,000Source | 2,815,000Source | 3,714,000Source |
| Operating Lease, Right-of-Use AssetUSD | 17,097,000Source | 21,536,000Source | 10,230,000Source | 18,137,000Source | 22,652,000Source | 10,642,000Source | 19,255,000Source | 23,753,000Source | 11,432,000Source | 20,404,000Source | 24,840,000Source | 25,715,000Source |
| Other Assets, NoncurrentUSD | 824,000Source | 842,000Source | 572,000Source | 827,000Source | 851,000Source | 513,000Source | 839,000Source | 917,000Source | 539,000Source | 839,000Source | 926,000Source | 3,568,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 182,232,000Source | 98,232,000Source | 82,814,000Source | 131,207,000Source | 33,735,000Source | 85,938,000Source | 112,941,000Source | 32,980,000Source | 98,281,000Source | 107,464,000Source | 34,025,000Source | 43,250,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 23,000Source | 23,000Source | 24,000Source | 23,000Source | 23,000Source | 24,000Source | 23,000Source | 18,000Source | 24,000Source | 23,000Source | 15,000Source | 13,000Source |
| Retained Earnings (Accumulated Deficit)USD | -515,240,000Source | -464,537,000Source | -468,510,000Source | -507,099,000Source | -450,457,000Source | -455,016,000Source | -492,113,000Source | -433,991,000Source | -460,195,000Source | -476,522,000Source | -409,574,000Source | -327,109,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,000Source | 27,000Source | -11,000Source | -7,000Source | -16,000Source | -7,000Source | -7,000Source | -10,000Source | -3,000Source | 4,000Source | -1,000Source | -299,000Source |
| Stockholders' Equity Attributable to ParentUSD | 26,756,000Source | 68,442,000Source | 82,371,000Source | 32,878,000Source | 80,014,000Source | 94,117,000Source | 45,618,000Source | 55,690,000Source | 87,798,000Source | 58,925,000Source | 57,805,000Source | 110,597,000Source |
| Additional Paid in Capital, Common StockUSD | 542,346,000Source | 533,503,000Source | 550,958,000Source | 540,328,000Source | 531,029,000Source | 549,613,000Source | 538,232,000Source | 490,221,000Source | 548,131,000Source | 535,770,000Source | 467,731,000Source | 437,992,000Source |
| Liabilities and EquityUSD | 208,988,000Source | 166,674,000Source | 165,185,000Source | 164,085,000Source | 113,749,000Source | 180,055,000Source | 158,559,000Source | 88,670,000Source | 186,079,000Source | 166,389,000Source | 91,830,000Source | 153,847,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 169,300,000Source | 80,364,000Source | 73,108,000Source | 117,878,000Source | 15,756,000Source | 76,842,000Source | 98,504,000Source | 14,117,000Source | 86,754,000Source | 90,878,000Source | 13,724,000Source | 17,921,000Source |
| Operating Lease, Liability, CurrentUSD | 3,783,000Source | 2,882,000Source | 2,539,000Source | 3,486,000Source | 2,872,000Source | 2,530,000Source | 3,257,000Source | 2,799,000Source | 2,978,000Source | 3,077,000Source | 2,703,000Source | 2,228,000Source |
| Accounts Payable, CurrentUSD | 53,075,000Source | 2,524,000Source | 16,972,000Source | 10,611,000Source | 3,587,000Source | 24,185,000Source | 16,617,000Source | 3,978,000Source | 21,496,000Source | 6,963,000Source | 1,584,000Source | 5,514,000Source |
| Operating Lease, Liability, NoncurrentUSD | 11,661,000Source | 15,319,000Source | 5,268,000Source | 12,627,000Source | 15,983,000Source | 5,438,000Source | 13,570,000Source | 16,691,000Source | 6,007,000Source | 14,449,000Source | 17,385,000Source | 19,477,000Source |
| Other Liabilities, NoncurrentUSD | 489,000Source | 421,000Source | 872,000Source | 472,000Source | 405,000Source | 841,000Source | 455,000Source | 309,000Source | 817,000Source | 439,000Source | 293,000Source | 231,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 590,000Source | — | — | 1,088,000Source | 7,100,000Source | 1,500,000Source | — | — | 5,700,000Source | — | — |
| Accrued Liabilities, CurrentUSD | 44,882,000Source | 6,764,000Source | 43,128,000Source | 35,727,000Source | 6,611,000Source | 36,526,000Source | 9,955,000Source | 4,980,000Source | 47,879,000Source | 11,378,000Source | 5,634,000Source | 8,084,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 28,800,000Source | 58,700,000Source | 64,000,000Source | 26,300,000Source | 62,600,000Source | 61,000,000Source | 41,900,000Source | 36,700,000Source | 63,800,000Source | 51,700,000Source | 39,700,000Source | 95,700,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 2,000,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Short-term InvestmentsUSD | 11,913,000Source | 36,676,000Source | 13,047,000Source | 6,160,000Source | 19,308,000Source | 10,276,000Source | 13,240,000Source | 9,929,000Source | 9,993,000Source | 26,494,000Source | 4,958,000Source | 49,704,000Source |
| Deferred Revenue, Noncurrent | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,482,000Source | 2,459,000Source | 8,314,000Source | 11,501,000Source | 14,132,000Source | 13,587,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -7,425,000Source | -4,261,000Source | 8,803,000Source | 2,753,000Source | 2,988,000Source | -51,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,674,000Source | 9,758,000Source | 14,639,000Source | 5,273,000Source | -2,444,000Source | 357,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,054,000Source | -9,599,000Source | 7,714,000Source | -44,764,000Source | -70,453,000Source | -94,779,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -676,000Source | 13,232,000Source | 16,632,000Source | -21,324,000Source | 43,952,000Source | -20,415,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 448,000Source | 130,000Source | 145,000Source | 554,000Source | 1,871,000Source | 9,601,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 338,000Source | 167,000Source | 199,000Source | 214,000Source | 366,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -338,000Source | -164,000Source | 4,239,000Source | 56,562,000Source | 15,243,000Source | 17,462,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,068,000Source | 3,469,000Source | 28,585,000Source | -9,526,000Source | -11,258,000Source | -97,732,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 16,880,000Source | 22,035,000Source | 50,929,000Source | 20,111,000Source | 50,746,000Source | 28,698,000Source | 53,814,000Source | 25,229,000Source | 34,755,000Source | 46,013,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 98,989Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,018,000Source | 2,475,000Source | 1,290,000Source | 2,121,000Source | 1,482,000Source | 2,459,000Source | 8,314,000Source | 11,501,000Source | 14,132,000Source | 13,587,000Source |
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 100,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 700,000Source | 700,000Source | 700,000Source | 1,300,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 28,800,000Source | 58,700,000Source | 64,000,000Source | 26,300,000Source | 61,000,000Source | 41,900,000Source | 63,800,000Source | 51,700,000Source | 39,700,000Source | 95,700,000Source |
| DepreciationUSD | — | — | 900,000Source | 1,000,000Source | 800,000Source | 900,000Source | 900,000Source | 900,000Source | 3,500,000Source | 3,700,000Source | 3,800,000Source | 1,967,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 22,000Source | — | — | — | — | — | — | -62,000Source | -6,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | -55,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | -10,000Source | 0Source | -38,000Source | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 4,277,000Source | 4,342,000Source | 6,603,000Source | 4,598,000Source | 4,641,000Source | 5,067,000Source | 17,608,000Source | 20,780,000Source | 22,584,000Source | 29,386,000Source |
| GoodwillUSD | — | — | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source | 4,508,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 4,254,000Source |
| Income Tax Expense (Benefit)USD | — | — | 17,000Source | 18,000Source | 29,000Source | 20,000Source | 29,000Source | 95,000Source | 476,000Source | 260,000Source | 261,000Source | 67,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,141,000Source | -14,080,000Source | -13,494,000Source | -14,986,000Source | 5,179,000Source | -15,591,000Source | 16,327,000Source | -66,948,000Source | -82,465,000Source | -107,758,000Source |
| Operating ExpensesUSD | — | — | 80,224,000Source | 19,408,000Source | 40,357,000Source | 54,333,000Source | 34,054,000Source | 35,811,000Source | 219,184,000Source | 94,993,000Source | 90,726,000Source | 114,694,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,000Source | 22,000Source | -333,000Source | -1,000Source | -11,000Source | -1,000Source | -44,000Source | 31,000Source | — | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 10,231,000Source | 7,338,000Source | 23,228,000Source | 64,270,000Source | 27,497,000Source | 55,014,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 17,237,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 3,000Source | 3,000Source | 30,000Source | 17,000Source | 223,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 7,379,000Source | 107,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 72,413,000Source | 4,933,000Source | 27,185,000Source | 39,730,000Source | 39,227,000Source | 20,876,000Source | 237,258,000Source | 28,700,000Source | — | — |
| Operating Income (Loss)USD | — | — | -7,811,000Source | -14,475,000Source | -13,172,000Source | -14,603,000Source | 5,173,000Source | -14,935,000Source | 18,074,000Source | -66,293,000Source | -83,347,000Source | -114,587,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,000Source | 22,000Source | -333,000Source | -1,000Source | -11,000Source | -1,000Source | -44,000Source | 31,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -8,124,000Source | -14,062,000Source | -13,465,000Source | -14,966,000Source | 5,208,000Source | -15,496,000Source | 16,803,000Source | -66,688,000Source | -82,204,000Source | -107,691,000Source |
| Income Tax Expense (Benefit)USD | — | — | 17,000Source | 18,000Source | 29,000Source | 20,000Source | 29,000Source | 95,000Source | 476,000Source | 260,000Source | 261,000Source | 67,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,141,000Source | -14,080,000Source | -13,494,000Source | -14,986,000Source | 5,179,000Source | -15,591,000Source | 16,327,000Source | -66,948,000Source | -82,465,000Source | -107,758,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.04Source | -0.06Source | -0.06Source | -0.07Source | 0.02Source | -0.07Source | 0.07Source | -0.33Source | -0.57Source | -0.84Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | 0.02Source | -0.07Source | 0.07Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 228,926,340Source | 227,452,883Source | 242,165,410Source | 228,367,812Source | 240,649,773Source | 227,923,636Source | 230,269,605Source | 202,137,531Source | 144,819,781Source | 127,683,813Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | 242,184,524Source | 227,923,636Source | 230,346,201Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 100,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 700,000Source | 700,000Source | 700,000Source | 1,300,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 476,000Source | 260,000Source | 261,000Source | 67,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 1,126,000Source | 2,247,000Source | 8,579,000Source | 8,850,000Source | 8,624,000Source | 5,805,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 22,000Source | — | — | — | — | — | — | -62,000Source | -6,000Source |
| General and Administrative ExpenseUSD | — | — | 4,277,000Source | 4,342,000Source | 6,603,000Source | 4,598,000Source | 4,641,000Source | 5,067,000Source | 17,608,000Source | 20,780,000Source | 22,584,000Source | 29,386,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 14,703,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 302,000Source | 1,022,000Source | 578,000Source | 310,000Source | 551,000Source | 437,000Source | 1,596,000Source | 2,543,000Source | 2,652,000Source | 1,247,000Source |
| Operating ExpensesUSD | — | — | 80,224,000Source | 19,408,000Source | 40,357,000Source | 54,333,000Source | 34,054,000Source | 35,811,000Source | 219,184,000Source | 94,993,000Source | 90,726,000Source | 114,694,000Source |
| Research and Development ExpenseUSD | — | — | 75,947,000Source | 15,066,000Source | 33,754,000Source | 49,735,000Source | 29,413,000Source | 30,744,000Source | 201,576,000Source | 74,213,000Source | 68,142,000Source | 81,054,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 7,379,000Source | 107,000Source |
Offerings
Registration 333-295737
Registration 333-295086
Filing attachments
ea029670901ex99-1.htm · 8-K · 2026-07-02
EX-99.1 3 ea029670901ex99-1.htm VAXART, INC. PRESS RELEASE DATED JULY 1, 2026 Exhibit 99.1 Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH SAN FRANCISCO, Calif., July 1, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company…
Read attachment ↗ea029144901ex99-1.htm · DEFA14A · 2026-05-19
Exhibit 99.1 Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote. Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a r…
Read attachment ↗ea029144901ex99-1.htm · 8-K · 2026-05-19
EX-99.1 2 ea029144901ex99-1.htm PRESS RELEASE, DATED MAY 19, 2026 Exhibit 99.1 Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote. Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or…
Read attachment ↗